Pulmonary Hypertension PBMC
About: Pulmonary Hypertension PBMC samples are collected from clinically confirmed pulmonary hypertension donors and cryopreserved. These PBMCs are ideal for investigating immune dysregulation, inflammatory cytokine production, and gene expression profiles in pulmonary hypertension pathogenesis.
| Lot Number | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73154 | Pulmonary Hypertension | 10M | Caucasian | 74 | Female |
Adempas 2.5mg TID Letairis 10mg QD Uppradi 1600mcg BID Omeprazole 20mg QD Rosuvastatin 10mg QD Cholestipol 2 1mg tablets QD Vitamin b12, D, calcium supplements
|
1 | |||
| 59295 | Pulmonary Hypertension | 5M | African American | 45 | Female |
Plaque-nil 200mg QD IViG Infusions every 3 weeks Lyrica 200mg QD OxyContin 20mg QD Oxycodone 10.325mg QD
|
4 | $765.00 | ||
| 69946 | Pulmonary Hypertension | 50M | Hispanic/Latino | 42 | Female | United States (US) |
Orenitram 5mg Letairis 10 mg Adcirca 20 mg
|
92 | $1,208.00 | |
| 69059 | Pulmonary Hypertension | 50M | Hispanic/Latino | 41 | Female | United States (US) |
Orenitram 0.5 mg 3x/day Letairis 10 mg/1x day Winrevair 1mg/3 weeks, last injection 5/11 Bumex as needed
|
82 | $1,208.00 | |
| 66907 | Pulmonary Hypertension | 50M | Hispanic/Latino | 43 | Female | United States (US) |
Letairis 10 mg 1x/day Adempas 2.5 mg 3x/day Winrevair 1.3 ml/ every 3 weeks, last injection 5/13/25
|
115 | $1,208.00 | |
| 68412 | Pulmonary Hypertension | 50M | Asian/Pacific Islander | 58 | Female | United States (US) |
TYVASO - NEBULIZER BOSENTAN 125 MG- PAH BABY ASPRIN ALDATONE 5 MG MUTLTI VIT
|
84 | $1,208.00 | |
| 55948 | Pulmonary Hypertension | 9M | Caucasian | 70 | Female | United States (US) |
Sildenafil 20mg TID lisinopril 5mg Hydroxychloroquine 200 mg BID pepcid Tylenol PRN O2
|
2 |
High-Quality Pulmonary Hypertension PBMC for Research
Pulmonary Hypertension Human PBMC products are sourced from donors clinically diagnosed with Pulmonary Hypertension and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on immune dysregulation, inflammatory cytokine production, and gene expression profiles in pulmonary hypertension pathogenesis
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed pulmonary hypertension donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified pulmonary hypertension diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional pulmonary hypertension-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in pulmonary hypertension pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Pulmonary Hypertension PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
Electronic medical records are an option to be included with the PBMC sample, as well as, flow cytometry and other phenotypic testing.
1 Answer
YES – we can often accommodate treatment-naive samples including various cancers, and you can specify immunosupression status or other requirements in the I/E criteria.
1 Answer
Self-reported infectious disease testing is always available and some of our products have additional testing.
1 Answer
HLA-typing is available for some of our PBMC products.
1 Answer
YES to both – Unique donors can be specified, and multiple vials from the same donor can be arranged. You can specify these requirements when ordering.
1 Answer
Healthy PBMCs achieve over 90% vialbity post-thaw. Although our disease-state PBMCs are processed with same stringent SOP, there is more variability depending upon disease. Learn more about our post thaw viability here. https://sanguinebio.com/pbmc-viability-quality-assurance/
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.